Hypomethylation of CTCFL promoters as a noninvasive biomarker in plasma from patients with hepatocellular carcinoma.

In conclusion, we provide evidence that the hypomethylation of CTCFL promoters in cell-free DNA is a biomarker for monitoring HCC patients, which can be used as a noninvasive prediction index for tumor recurrence and provide the individualized decision-making for clinicians.
PMID: 32386482 [PubMed - as supplied by publisher]

Source: Neoplasma - May 5, 2020 Category: Cancer & Oncology Authors: Chen MM, Zhao RC, Chen KF, Huang Y, Liu ZJ, Wei YG, Jian Y, Sun AM, Qin L, Li B, Qin Y Tags: Neoplasma Source Type: research